Is Aspirin monotherapy effective for stroke prevention in the real world? A UK cohort study evaluating the incidence of stroke in the absence of anticoagulation in atrial fibrillation (AF)

Poor anticoagulation control in warfarin treated atrial fibrillation patients with reduced renal function

In-hospital mortality, length of stay and costs of treating atrial fibrillation or flutter patients admitted for intracranial hemorrhage

One-year permeability rate of left atrial appendage closure devices: high incidence of peridevice leak and lack of endothelialization

Net clinical benefit of rivaroxaban compared with warfarin in patients with atrial fibrillation

Major bleeding risk in patients 75 years of age or older with non-valvular atrial fibrillation initiating oral anticoagulants: a real-world comparison of warfarin, apixaban, dabigatran, or rivaroxaban

Non-vitamin K antagonist oral anticoagulation usage in elderly patients with atrial fibrillation: Danish nationwide data with temporal trends from 2011 to 2015

Left atrial thrombus resolution in atrial fibrillation or flutter: results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF)

Real - world evidence of stroke prevention in patients with non-valvular atrial fibrillation

Patients' convenience and satisfaction as important factors related to switching from vitamin K antagonists to NOACs - a PREFER in AF Registry analysis